Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +46.40%
#2 Pons Pons +33.09%
#3 TENDIES TENDIES +31.51%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.78%
#5 Starpower Starpower +28.97%
#6 StonkBroker StonkBroker +23.95%
#7 Mubarak Mubarak +22.28%
#8 SkyAI SkyAI +22.11%
#9 PondCoin PondCoin +21.09%
#10 Ocean Protocol Ocean Protocol +19.89%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Celularity Inc. Celularity Inc.

Celularity Inc.

CELU
Classificação em ações #28923
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to... Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Preço da ação
$0.8353
Valor de mercado
$24.18M
Variação (1 dia)
13.38%
Variação (1 ano)
-76.86%
País
US
Negociar Celularity Inc. (CELU)

Categoria

Healthcare
Lucros da Celularity Inc. (CELU)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Celularity Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Celularity Inc. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH